Johnson & Johnson's (JNJ) shares were edging lower Tuesday after S&P Global Ratings said it placed nearly all of the company's ratings on creditwatch with negative implications following the drugmaker's $14.6 billion deal to acquire Intra-Cellular Therapies (ITCI).
The ratings agency said that the negative creditwatch reflects concerns that while the company has reduced its debt after each acquisition, its leverage may occasionally exceed 1.0 times, which the ratings agency views as inconsistent with the current 'AAA' rating.
S&P said it plans to resolve the creditwatch status after reviewing the company's full-year 2024 results, 2025 guidance, as well as more details about the transaction, and additional information on management's financial policies regarding future mergers and acquisitions. It also said it will assess the impact of the ongoing talcum powder litigation settlement on the company's adjusted leverage.
Price: 143.64, Change: -0.83, Percent Change: -0.57
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。